Gilead Sciences [GILD] vs Bristol-Myers Squibb [BMY] Detailed Stock Comparison

Gilead Sciences, Inc.

NASDAQ
Loading...

Bristol-Myers Squibb Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Gilead Sciences, Inc. wins in 9 metrics, Bristol-Myers Squibb Company wins in 12 metrics, with 0 ties. Bristol-Myers Squibb Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Gilead Sciences, Inc. Bristol-Myers Squibb Company Better
P/E Ratio (TTM) 19.66 17.06 Bristol-Myers Squibb Company
Price-to-Book Ratio 7.29 6.51 Bristol-Myers Squibb Company
Debt-to-Equity Ratio 112.92 254.98 Gilead Sciences, Inc.
PEG Ratio 0.85 0.01 Bristol-Myers Squibb Company
EV/EBITDA 12.44 8.20 Bristol-Myers Squibb Company
Profit Margin (TTM) 28.90% 14.64% Gilead Sciences, Inc.
Operating Margin (TTM) 37.38% 28.16% Gilead Sciences, Inc.
EBITDA Margin (TTM) 37.38% 28.16% Gilead Sciences, Inc.
Return on Equity 40.66% 40.44% Gilead Sciences, Inc.
Return on Assets (TTM) 12.52% 10.29% Gilead Sciences, Inc.
Free Cash Flow (TTM) $9.46B $12.85B Bristol-Myers Squibb Company
Dividend Yield 2.57% 5.82% Bristol-Myers Squibb Company
1-Year Return 14.19% 14.83% Bristol-Myers Squibb Company
Price-to-Sales Ratio (TTM) 5.62 2.50 Bristol-Myers Squibb Company
Enterprise Value $181.31B $156.74B Gilead Sciences, Inc.
EV/Revenue Ratio 6.16 3.25 Bristol-Myers Squibb Company
Gross Profit Margin (TTM) 79.51% 67.23% Gilead Sciences, Inc.
Revenue per Share (TTM) $24 $24 Bristol-Myers Squibb Company
Earnings per Share (Diluted) $6.78 $3.46 Gilead Sciences, Inc.
Beta (Stock Volatility) 0.40 0.27 Bristol-Myers Squibb Company
Short % of Float 1.74% 1.54% Bristol-Myers Squibb Company

Gilead Sciences, Inc. vs Bristol-Myers Squibb Company Stock Performance Analysis

Loading Price Chart...

GILD
BMY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gilead Sciences, Inc.-1.03%-2.97%-4.07%-14.40%3.77%2.22%
Bristol-Myers Squibb Company-1.56%1.21%-1.33%-5.81%3.59%5.20%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gilead Sciences, Inc.14.19%59.26%88.55%51.95%535.26%767.93%
Bristol-Myers Squibb Company14.83%-13.65%-14.05%-19.16%107.59%126.89%

Performance & Financial Health Analysis: Gilead Sciences, Inc. vs Bristol-Myers Squibb Company

MetricGILDBMY
Market Information
Market Cap i$165.87B$119.87B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i4,914,2128,535,002
90 Day Avg. Volume i5,711,56411,824,357
Last Close$124.30$56.24
52 Week Range$104.46 - $157.29$42.52 - $62.89
% from 52W High-20.97%-10.57%
All-Time High$157.27 (Feb 11, 2026)$81.44 (Nov 28, 2022)
% from All-Time High-20.96%-30.94%
Growth Metrics
Quarterly Revenue Growth0.05%0.01%
Quarterly Earnings Growth0.22%14.10%
Financial Health
Profit Margin (TTM) i0.29%0.15%
Operating Margin (TTM) i0.37%0.28%
Return on Equity (TTM) i0.41%0.40%
Debt to Equity (MRQ) i112.92254.98
Cash & Liquidity
Book Value per Share (MRQ)$18.29$9.07
Cash per Share (MRQ)$7.74$5.24
Operating Cash Flow (TTM) i$10.02B$14.16B
Levered Free Cash Flow (TTM) i$7.54B$11.15B
Dividends
Last 12-Month Dividend Yield i2.57%5.82%
Last 12-Month Dividend i$3.98$3.11

Valuation & Enterprise Metrics Analysis: Gilead Sciences, Inc. vs Bristol-Myers Squibb Company

MetricGILD (Apr 24, 2026)BMY (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i19.6617.06
Forward P/E i13.859.61
PEG Ratio i0.850.01
Price to Sales (TTM) i5.622.50
Price to Book (MRQ) i7.296.51
Market Capitalization
Market Capitalization i$165.87B$119.87B
Enterprise Value i$181.31B$156.74B
Enterprise Value Metrics
Enterprise to Revenue i6.163.25
Enterprise to EBITDA i12.448.20
Risk & Other Metrics
Beta i0.400.27
Book Value per Share (MRQ) i$18.29$9.07

Financial Statements Comparison: Gilead Sciences, Inc. vs Bristol-Myers Squibb Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGILD (2025)BMY (2025)
Revenue/Sales i29.44B48.20B
Cost of Goods Sold i6.23B13.94B
COGS % of Revenue i21.2%28.9%
Gross Profit i23.21B34.26B
Gross Margin i78.8%71.1%
Research & Development i5.80B9.95B
Operating Income (EBIT) i11.70B13.72B
Operating Margin i39.7%28.5%
EBITDA i14.81B19.95B
EBITDA Margin i50.3%41.4%
Pre-Tax Income i9.80B9.33B
Pre-Tax Income % of Revenue i33.3%19.4%
Income Tax i1.29B2.27B
Income Tax % of Revenue i4.4%4.7%
Net Income (Profit) i8.51B7.06B
Profit Margin i28.9%14.6%

Balance Sheet & Liquidity Metrics

MetricGILD (2025)BMY (2025)
Cash & Equivalents i7.56B10.21B
Total Current Assets i18.34B29.39B
Total Current Assets % of Revenue i62.3%61.0%
Total Current Liabilities i11.81B23.42B
Total Current Liabilities % of Revenue i40.1%48.6%
Long-Term Debt i22.13B44.68B
Long-Term Debt % of Revenue i75.2%92.7%
Total Shareholders Equity i22.62B18.51B
Retained Earnings i13.73B16.90B
Retained Earnings % of Revenue i46.6%35.1%
Property, Plant & Equipment i1.71B1.58B

Cash Flow Statement Comparison

MetricGILD (2025)BMY (2025)
Operating Cash Flow i10.19B14.51B
Operating Cash Flow % of Revenue i34.6%30.1%
Capital Expenditures i-563.00MN/A
Free Cash Flow i9.46B12.85B
FCF Margin i32.1%26.7%
Debt Repayment i-1.79B-10.94B
Common Stock Repurchase i-1.92B0

Short Interest & Institutional Ownership Analysis

MetricGILDBMY
Shares Short i21.52M31.50M
Short Ratio i3.562.29
Short % of Float i1.74%1.54%
Shares Outstanding i1.24B2.04B
Float Shares i1.24B2.03B
% Held by Insiders i0.13%0.09%
% Held by Institutions i92.71%83.86%
% Held by Public i7.16%16.05%

Dividend Analysis & Yield Comparison: Gilead Sciences, Inc. vs Bristol-Myers Squibb Company

MetricGILDBMY
Last 12-Month Dividend i$3.98$3.11
Last 12-Month Dividend Yield i2.57%5.82%
3-Year Avg Annual Dividend i$3.35$2.60
3-Year Avg Dividend Yield i0.85%1.13%
3-Year Total Dividends i$10.06$7.79
Ex-Dividend DateMar 13, 2026Jan 02, 2026